This article is more than 5 years old. Information may no longer be current.
Allegro continues studies of integrin peptide therapy
Allegro Ophthalmics has completed enrollment of a phase 1b/2a study of the impact of its integrin peptide therapy on wet age-related macular degeneration, according to a company news release. In addition, Allegro has begun a second study of the therapy’s impact on diabetic macular edema.
Safety is the primary endpoint of the dose-ranging, monotherapy wet AMD study of ALG-1001, with secondary endpoints of improvement in central macular thickness and best corrected visual acuity.
Results will be presented at the Association for Research in Vision and Ophthalmology annual meeting in May.
The DME study will examine the safety and efficacy of intravitreal injections of ALG-1001 in combination with Avastin (bevacizumab, Genentech) compared with bevacizumab alone.
The study has 30 subjects with DME that has not sufficiently been treated by repeated anti-VEGF injections.